- Home
- VIRX vs PAVM Comparison
VIRX vs PAVM Comparison
Compare VIRX & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIRX
- PAVM
- Stock Information
- Founded
- VIRX 2007
- PAVM 2014
- Country
- VIRX United States
- PAVM United States
- Employees
- VIRX N/A
- PAVM N/A
- Industry
- VIRX Biotechnology: Pharmaceutical Preparations
- PAVM Medical/Dental Instruments
- Sector
- VIRX Health Care
- PAVM Health Care
- Exchange
- VIRX Nasdaq
- PAVM Nasdaq
- Market Cap
- VIRX 7.0M
- PAVM 7.1M
- IPO Year
- VIRX N/A
- PAVM 2016
- Fundamental
- Price
- VIRX $0.19
- PAVM $0.62
- Analyst Decision
- VIRX Buy
- PAVM Strong Buy
- Analyst Count
- VIRX 4
- PAVM 1
- Target Price
- VIRX $5.00
- PAVM $19.00
- AVG Volume (30 Days)
- VIRX 2.3M
- PAVM 305.6K
- Earning Date
- VIRX 11-13-2024
- PAVM 11-14-2024
- Dividend Yield
- VIRX N/A
- PAVM N/A
- EPS Growth
- VIRX N/A
- PAVM N/A
- EPS
- VIRX N/A
- PAVM 0.53
- Revenue
- VIRX N/A
- PAVM $4,034,000.00
- Revenue This Year
- VIRX N/A
- PAVM $52.90
- Revenue Next Year
- VIRX N/A
- PAVM $248.84
- P/E Ratio
- VIRX N/A
- PAVM $1.17
- Revenue Growth
- VIRX N/A
- PAVM 166.27
- 52 Week Low
- VIRX $0.13
- PAVM $0.57
- 52 Week High
- VIRX $1.31
- PAVM $4.01
- Technical
- Relative Strength Index (RSI)
- VIRX 48.39
- PAVM 34.29
- Support Level
- VIRX $0.20
- PAVM $0.60
- Resistance Level
- VIRX $0.24
- PAVM $0.76
- Average True Range (ATR)
- VIRX 0.03
- PAVM 0.08
- MACD
- VIRX -0.00
- PAVM 0.01
- Stochastic Oscillator
- VIRX 34.27
- PAVM 14.58
About VIRX Viracta Therapeutics Inc.
Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The Company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.